Samsung and Merck launch Remicade biosim at 35% discount
After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched their Renflexis in the U.S. at a 35% markdown to the blockbuster J&J anti-inflammatory med. Their move follows last year’s launch by Pfizer for its version, Inflectra, at a 15% discount. The prices are before negotiated rebates. As J&J’s top-selling med, Remicade brought in nearly $5 billion in the U.S. last year. With those critical sales under threat,...
